Total
0
Shares
Levitee Labs - CEO, Pouya Farmand.
CEO, Pouya Farmand.
Source: Levitee Labs.
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Levitee Labs (LVT) appoints Dr. Mohammed Mosli as Chief People Officer of Levitee Clinics and Pharmacies in Alberta, Canada
  • Dr. Mosli has over a decade of healthcare experience specializing in addiction, leading innovation in reorienting health systems, and increasing health equality
  • Dr. Mosli spent the last five years as a Medical Officer of Canada’s largest province-wide, fully-integrated health system that serves over four million patients
  • He earned his Bachelor of Medicine and Bachelor of Surgery (MBBS) degree in the field of Medical Sciences from King Abdulaziz University in Saudi Arabia
  • Levitee Labs Inc. (LVT) is down 2.20 per cent, trading at C$0.44 at 10:17 am ET

Levitee Labs Inc (LVT) appoints Mohammed H Mosli, MD, FRCPC, ISAM, as Chief People Officer (CPO) of Levitee Clinics™ and Levitee Pharmacies™.

In this role, Dr. Mosli will oversee managing the strategy and processes related to building and retaining an exceptional team of professionals and will optimize people-centred activities such as hiring, training, professional development, and performance management.

He will oversee 60 active employees in Alberta, to ensure these efforts support the continued growth of Levitee Clinics™ and Levitee Pharmacies™ across North America.

Dr. Mosli is a multilingual Public Health and Preventive Medicine physician specialized in Addictions Health, health services improvement, health promotion, environmental public health, and health policy.

Throughout his career, Dr. Mosli served or currently serves as a director, educator, or senior-level manager for an array of organizations, including those in provincial, institutional, and private segments. He is a valuable physician member of the Opioid Addictions Medicine team for Levitee Clinics™ and Levitee Pharmacies™ in Alberta.

“Dr. Mosli has spent his career working with multi-disciplinary teams to provide focused medical care to vulnerable populations, including opioid agonist therapy, alcohol addiction therapy, Hepatitis C treatment, and many more,” said Pouya Farmand, Chief Executive Officer at Levitee Labs™.

“He exudes leadership and has consistently demonstrated unparalleled skills to organize teams and manage individuals at major organizations to achieve goals with the utmost efficiency, qualities that will be invaluable to us as we continue to roll-up companies and expand our operations nationwide.”

“I have always been passionate about leading innovation in reorienting health systems, increasing health equality, and protecting the wellbeing of local, national, and global population with an evidence-based approach,” commented Dr. Mosli.

“My goals align perfectly with those of Levitee Labs™ and I look forward to being a leader during this phase of rapid growth for the company.”

Dr. Mosli earned his FRCPC (Fellow of the Royal College of Physicians of Canada) degree from the University of Calgary in Public Health and Preventive Medicine. He earned his Bachelor of Medicine and Bachelor of Surgery (MBBS) degree in the field of Medical Sciences from King Abdulaziz University in Saudi Arabia.

Levitee Labs™ is establishing itself as a leader in the integrative wellness space. Through leveraging an M&A regimen that focuses on the centralization of complementary integrative wellness assets, Levitee Labsaims to transform mental health and addiction treatments through the integration of psychedelic medicines and therapies into a medical home care model.

Levitee Labs Inc. (LVT) is down 2.20 per cent, trading at C$0.44 at 10:17 am ET.

More From The Market Herald
Theratechnologies - Chief Medical Officer and Senior Vice President Dr. Christian Marsolais

" Theratechnologies (TSX:TH) confirms effectiveness of PDCs against vasculogenic mimicry

Theratechnologies (TH) reports its investigational peptide-drug conjugates (PDCs) are effective in inhibiting vasculogenic mimicry (VM) in ovarian and breast cancer models.

" Algernon Pharmaceuticals (CSE:AGN) receives $2M payment and applies for Nasdaq listing

Algernon Pharmaceuticals (AGN) has recently received a $2M cash payment from a refundable tax credit program for its clinical research work in Australia.

" MediPharm Labs (TSX:LABS) appoints new CEO

 MediPharm Labs (LABS) is pleased to announce that Bryan Howcroft will join MediPharm Labs as Chief Executive Officer and Director, effective November 15,

" Levitee Labs (CSE:LVT) enters into credit facility for up to $12 Million

Levitee Labs Inc. (LVT) has entered into a financing agreement for up to $12 million to fund further business expansion.